ASH 2018 | Rivaroxaban for thromboprophylaxis in high-risk cancer patients: CASSINI results

Name: Rivaroxaban for thromboprophylaxis in high-risk cancer patients: CASSINI results
Uploaded: 2018-12-06T16:07:12.000Z
Duration: 10 min 50 s
Description: The CASSINI trial investigated the use of rivaroxaban to prevent the development of blood clots in high-risk ambulatory cancer patients receiving systemic therapy. Alok Khorana, MD, of the Cleveland Clinic, Cleveland, OH, presents the data at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.

Alok Khorana • 6 Dec 2018

ASH 2018

General Rivaroxaban

CASSINI

The CASSINI trial investigated the use of rivaroxaban to prevent the development of blood clots in high-risk ambulatory cancer patients receiving systemic therapy. Alok Khorana, MD, of the Cleveland Clinic, Cleveland, OH, presents the data at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.